Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary

Masashi Takano, Yoshihiro Kikuchi, Nobuo Yaegashi, Mitsuaki Suzuki, Hiroshi Tsuda, Satoru Sagae, Yasuhiro Udagawa, Kazuo Kuzuya, Junzo Kigawa, Satoshi Takeuchi, Hitoshi Tsuda, Takuya Moriya, Toru Sugiyama

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)

Abstract

Clear cell carcinoma (CCC) of the ovary has distinct characteristics showing resistance to conventional platinum-based regimen. Our aim was to evaluate the effects of combination therapy with irinotecan hydrochloride and cisplatin (CPT-P), comparing to regimen with paclitaxel and platinum (TP). We retrospective reviewed 172 patients with complete surgical staging procedures including lymphadenenctomy. Forty-six patients received CPT-P and 126 patients were treated with TP. Survival of the two groups was compared. Between CPT-P group and TP group, there was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, and follow-up period. There was no significant difference in progressionfree survival of patients with stage I tumors (p=0.95) and suboptimally debulked stage II-IV tumors (p=0.92). Although there was no significant difference of overall survival, progression-free survival of CPT-P group was significantly better than that of TP group in optimally debulked stage II-IV (p=0.03). Multiple regression survival analysis revealed CPT-P regimen (p=0.02) and residual tumor diameter (p<0.01) were both independent prognostic factors in stage II-IV tumors. The combination of CPT-P was shown to have a potential therapeutic benefit for advanced CCC of the ovary, especially for cases with optimal debulking surgery. However, this is a limited retrospective study, therefore we recommend that the CPT-P regimen be evaluated in a larger prospective study.

Original languageEnglish
Pages (from-to)1301-1306
Number of pages6
JournalOncology reports
Volume16
Issue number6
DOIs
Publication statusPublished - 2006 Dec

Keywords

  • Adjuvant chemotherapy
  • Clear cell carcinoma
  • Irinotecan hydrochloride
  • Multicentre
  • Ovarian cancer
  • Paclitaxel
  • Retrospective

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary'. Together they form a unique fingerprint.

Cite this